Axcess News – Lifestyle
Author:
Tarsus Pharmaceuticals, Inc
Tarsus to Participate in Upcoming Investor Conferences
May 7, 2026
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
May 6, 2026
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
March 31, 2026
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
March 23, 2026
Tarsus to Participate in Upcoming Investor Conferences
March 6, 2026
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
March 5, 2026
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
March 4, 2026